The FDA GLP-1 vision warning means a rare but serious eye risk must be added to drug labeling. GLP-1 medicines mimic a gut hormone's effects on blood sugar and appetite. The announcement does not tell everyone taking them to stop.

The concern is non-arteritic anterior ischemic optic neuropathy, or NAION: a sudden loss of blood flow to the optic nerve. That nerve carries sight signals to the brain. Sight loss can be permanent and painless. Sudden vision loss needs medical attention right away.

FDA GLP-1 vision warning: what changed

As of November 12, 2026, the day this article was written, FDA's November 9 Drug Safety Communication requires a NAION warning across the GLP-1 drug class. Manufacturers must add it to Warnings and Precautions, the label section explaining serious risks and how clinicians respond.

FDA's table lists these products:

Brand listed by FDA Active ingredient
Byetta* Exenatide
Victoza Liraglutide
Trulicity Dulaglutide
Saxenda Liraglutide
Xultophy Liraglutide + insulin degludec
Soliqua Lixisenatide + insulin glargine
Ozempic Semaglutide
Rybelsus Semaglutide
Wegovy Semaglutide
Mounjaro Tirzepatide
Zepbound Tirzepatide
Foundayo Orforglipron

FDA notes that Byetta's application was already voluntarily withdrawn for reasons unrelated to safety or effectiveness; only generic exenatide products are marketed now.

This action requires a warning, rather than withdrawing these medicines or adding a contraindication, a condition in which a medicine must not be used. It also doesn't mean every posted label has already changed. For someone prescribed semaglutide, the new information belongs in the next treatment discussion.

What the NAION risk numbers mean

FDA pooled 126 randomized trials, studies that assigned people to treatments by chance. Together, they included 134,253 people. The agency found 15 probable cases: 10 among GLP-1 users and five among comparison patients.

The rates reported by FDA were 6.4 cases per 100,000 person-years with GLP-1 medicines, versus 3.8 with comparison treatments. Those treatments were placebo, a dummy treatment, or another blood-sugar medicine.

Think of 100,000 people followed for one year: roughly six cases versus four. Person-years add up everyone's time under observation. These are rare events, with a calculated difference of 2.6 cases per 100,000 person-years. They aren't a prediction for one person's eyes.

FDA also studied insurance records through Sentinel, its system for monitoring medicine safety. Among adults with type 2 diabetes, the answer depended on the comparison drug. Against SGLT-2 inhibitors, medicines that help kidneys remove sugar, the increase wasn't statistically clear; chance remained a possible explanation. Against DPP-4 inhibitors, medicines that prolong gut-hormone signals, FDA found an increase.

Those findings don't supply a precise risk for every medicine, prescription or person. Our GLP-1 vision-loss study explainer examines a separate study of patient records.

What this means for semaglutide and tirzepatide

FDA names symptoms that call for action right away:

  • Sudden, painless loss of sight in one eye, sometimes noticed on waking.
  • Missing or blurred patches, blind spots or tunnel vision.
  • Colors looking distorted.
  • Reduced sharpness in the center of vision, including hazy spots.

Its patient instruction is direct: “Patients should contact their health care professional right away if they have any of these symptoms.” Waiting for a routine follow-up isn't the response FDA describes.

FDA tells clinicians to instruct patients to report sudden symptoms immediately. Suspected NAION requires prompt referral to an ophthalmologist, a medical eye specialist. It says to consider discontinuing the GLP-1 medicine when NAION develops, unless treatment benefits clearly outweigh the risk. That is a treatment decision with the clinician, not a blanket instruction to continue.

The history matters too. FDA lists smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease as possible risk factors. Sleep apnea means breathing repeatedly stops during sleep; anemia means too few healthy red blood cells. NAION in one eye increases the risk in the other.

Mounjaro and Zepbound contain tirzepatide, and both appear in FDA's table. Changing from semaglutide to tirzepatide does not step outside this class-wide warning. A prescribed route provides a clinician to review that history and respond to symptoms; it cannot remove the eye risk.

What the warning does not mean

A warning does not settle every question about cause. The 2024 JAMA Ophthalmology study by Hathaway and colleagues found an association at one specialist eye clinic. An association means things happened together; it doesn't prove one caused the other.

As of November 12, 2026, the day this article was written, the evidence also includes a British Journal of Ophthalmology analysis published April 28, 2026. That pooled review of Novo Nordisk's placebo-controlled trials, whose authors included Novo Nordisk employees, found no higher NAION rate with semaglutide or liraglutide than with placebo. That analysis covered those two molecules; FDA's review covered the wider class. The earlier result does not cancel the new warning.

Europe acted earlier on semaglutide. In June 2025, EMA's safety committee classified NAION as a very rare side effect. It says sudden vision loss or rapidly worsening eyesight requires contact without delay, and semaglutide should be stopped if NAION is confirmed.

As of November 20, 2026, the day this update was written, Denmark’s Patient Compensation Association, a public no-fault compensation body rather than a court or medicine regulator, lists 94 NAION claims after Wegovy or Ozempic in its November 18 update: 31 recognized, 29 rejected and 34 still being assessed. Its individual compensation decisions do not establish that the medicine causes the condition in general.

This warning is separate from tirzepatide's diabetic retinopathy warning, about diabetes-related damage to blood vessels inside the eye. The vision-loss lawsuits concern legal allegations. FDA's safety action does not decide those cases.

What a compounded prescription changes

Semaglutide and tirzepatide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications. Each preparation is different from an FDA-approved product: the formulations offered here are not FDA-approved. FDA explains that compounded drugs do not undergo its review for safety, effectiveness or quality before marketing.

A licensed provider may still prescribe — that decision is between you and your doctor.

A compounded preparation has pharmacy labeling rather than its own FDA-reviewed brand label. That distinction doesn't make a warning about the same molecule irrelevant. It gives the prescriber another specific risk to discuss, without assuming branded trial rates apply exactly to the compounded preparation.

At Promise, a licensed provider reviews every request, and not everyone qualifies. The prescription route connects the history, the dispensed medication and follow-up to accountable professionals. A vial obtained without a prescription leaves out that prescribing review.

What to watch next

The next checkpoints are the revised U.S. labels and evidence that separates individual medicines and patient groups. The broader semaglutide and vision guide covers the different eye conditions; this November FDA action adds a class-wide warning to that discussion.

For an existing prescription, the useful conversation covers past eye injury, the possible risk factors FDA names and how urgent symptoms will be handled. New sudden sight loss calls for contact right away, even when it doesn't hurt.